

Supplementary Material

Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke

Emma Martínez-Alonso ¹, Alejandro Escobar-Peso ¹, Alicia Aliena-Valero ², Germán Torregrosa ², Mourad Chioua ³, Rocío Fernández-Serra ⁴, Daniel González-Nieto ^{4,5}, Juan B. Salom ^{2,6}, Jaime Masjuan ^{7,8}, José Marco-Contelles ³ and Alberto Alcázar ^{1,*}

¹ Department of Research, Hospital U. Ramón y Cajal, IRYCIS, Ctra. Colmenar km 9.1, Madrid 28034, Spain; emma.martinez@hrc.es (E.M.-A.); alejandro.escobar@hrc.es (A.E.-P.); alberto.alcazar@hrc.es (A.A.)

² Unidad Mixta de Investigación Cerebrovascular, Instituto de Investigación Sanitaria La Fe - Universidad de Valencia, Valencia 46016, Spain; alicia_aliena@iislafe.es (A.A.-V.); torregrosa_ger@gva.es (G.T.); salom_jba@gva.es (J.B.S.)

³ Laboratory of Medicinal Chemistry (IQOG, CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain; m.chioua@csic.es (M.C.); jlmarco@iqog.csic.es (J.M.-C.)

⁴ Center for Biomedical Technology, Universidad Politécnica de Madrid, Pozuelo de Alarcón 28223, Spain; rocio.fernandez@ctb.upm.es (R.F.-S.); daniel.gonzalez@ctb.upm.es (D.G.-N.)

⁵ CIBER of Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Spain

⁶ Departamento de Fisiología, Universidad de Valencia, Valencia 46016, Spain

⁷ Department of Neurology, Hospital Universitario Ramón y Cajal, IRYCIS, Ctra. Colmenar km 9.1, Madrid 28034, Spain; jaime.masjuan@salud.madrid.org (J.M.)

⁸ Department of Medicine, Facultad de Medicina, Universidad de Alcalá, Ctra. Madrid-Barcelona km 33.6, Alcalá de Henares 28871, Spain

Contents

A. Toxicokinetics study. Clinical biochemistry parameters (Table S1).....	S2
---	----

A. Toxicokinetics study. Clinical biochemistry parameters

Table S1
Clinical biochemistry parameters.
Females. Main allocation. Day 5. Mean \pm SD

Day : 5 Relative to Start Date

Sex: Female		GLUC	URE	CRE	CHOL	TRIGL	TP	ALB	GLOB	BIL	ALP	ALT	AST	GGT
		(mmol/L)	(mmol/L)	(μ mol/L)	(mmol/L)	(mmol/L)	(g/L)	(g/L)	(g/L)	(μ mol/L)	(U/L)	(U/L)	(IU/L)	(U/L)
Group: A	Mean	7.84	7.12	27.82	3.05	0.78	55.04	35.67	19.37	0.52	93.24 a ¹	44.07	70.71 a ¹	0.00
	SD	0.57	0.82	1.39	0.37	0.12	0.65	2.18	2.04	0.23	16.49	6.84	4.52	0.00
	N	5	5	5	5	5	5	5	5	5	5	5	5	5
Group: B	Mean	7.08	6.90	28.64	3.18	0.86	55.80	35.39	20.41	0.81	86.67	54.64	105.37 d ²	0.00
	SD	0.40	0.89	2.79	0.29	0.22	1.14	2.03	2.09	0.32	5.53	10.29	23.74	0.00
	N	5	5	5	5	5	5	5	5	5	5	5	5	5
Group: C	Mean	7.22	6.20	27.57	2.83	0.69	55.66	36.08	19.58	0.94	73.38 d ²	50.43	92.48	0.00
	SD	0.72	0.83	1.23	0.32	0.26	2.97	2.59	2.22	0.19	8.03	6.39	13.60	0.00
	N	5	5	5	5	5	5	5	5	5	5	5	5	5
Group: D	Mean	6.77	7.08	27.58	2.90	0.72	55.22	34.32	20.89	0.96	80.71	57.27	116.10 d d ³	0.00
	SD	1.07	0.72	1.85	0.15	0.16	1.25	2.75	2.45	0.35	8.56	6.63	28.68	0.00
	N	5	5	5	5	5	5	5	5	5	5	5	5	5

1 [a - Group Factor Test: Analysis of Variance $p < 0.05$]

2 [d - Test: Dunnett 2 Sided $p < 0.05$]

3 [dd - Test: Dunnett 2 Sided $p < 0.01$]

Group A, Vehicle. Group B: QN23, 2 mg/kg/day. Group C: QN23 6 mg/kg/day. Group D: QN23 18 mg/kg/day